Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Correlation Between Auto-antibodies to Survivin and MUC1 Variable Number Tandem Repeats in Colorectal Cancer

  • Wang, Yu-Qian (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University) ;
  • Zhang, Hai-Hong (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University) ;
  • Liu, Chen-Lu (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University) ;
  • Xia, Qiu (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University) ;
  • Wu, Hui (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University) ;
  • Yu, Xiang-Hui (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University) ;
  • Kong, Wei (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: The aim of this study was to investigate the frequency and correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats (VNTR) in colorectal cancer (CRC), which can provide valuable information for the design of immunotherapeutic vaccines for this disease. Methods: Enzyme-linked immunosorbent assays (ELISA) were used to examine the level of auto-antibodies against survivin and MUC1 VNTR in the serum of 135 CRC patients and 95 healthy volunteers. Results: Using mean absorbance + 2 standard deviations (SD) of the healthy samples as a cut-off value, the positive rates of survivin and MUC1 VNTR auto-antibodies in CRC were 31.1% and 18.5%, respectively. Altogether, the survivin and MUC1 VNTR positive samples accounted for 36.3% of the CRC patients, and 7.4% were positive for both. Conclusion: A significant positive correlation was found between levels of specific antibodies against survivin and MUC1 VNTR in the serum of CRC patients (r = 0.3652, P < 0.0001), suggesting that vaccines against both targets would elicit immune responses more effectively.

Keywords

References

  1. Al-Joudi FS, Iskandar ZA (2006). Autoantibodies to survivin in the sera of patients with infiltrating ductal carcinoma of the breast. Med J Malaysia, 61, 302-6.
  2. Ambrosini G, Adida C, Altieri DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3, 917-21. https://doi.org/10.1038/nm0897-917
  3. Apostolopoulos V, McKenzie IF (1994). Cellular mucins: targets for immunotherapy. Crit Rev Immunol, 14, 293-309. https://doi.org/10.1615/CritRevImmunol.v14.i3-4.40
  4. Chakravarti A, Noll E, Black PM, et al (2002). Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol, 20, 1063-8. https://doi.org/10.1200/JCO.20.4.1063
  5. Chen JS, Chen KT, Fan WC, et al (2010). Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer. Clin Chem Lab Med, 48, 719-25.
  6. Chung MH, Gupta RK, Hsueh E, et al (2003). Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol, 21, 313-9. https://doi.org/10.1200/JCO.2003.10.068
  7. Coronella-Wood JA, Hersh EM (2003). Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother, 52, 715-38. https://doi.org/10.1007/s00262-003-0409-4
  8. Dermime S, Armstrong A, Hawkins RE, Stern PL (2002). Cancer vaccines and immunotherapy. Br Med Bull, 62, 149-62. https://doi.org/10.1093/bmb/62.1.149
  9. DiFronzo LA, Gupta RK, Essner R, et al (2002). Enhanced humoral immune response correlates with improved diseasefree and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol, 20, 3242-8. https://doi.org/10.1200/JCO.2002.01.065
  10. Finn OJ, Jerome KR, Henderson RA, et al (1995). MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev, 145, 61-89. https://doi.org/10.1111/j.1600-065X.1995.tb00077.x
  11. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988). A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem, 263, 12820-3.
  12. Green MC, Murray JL, Hortobagyi GN (2000). Monoclonal antibody therapy for solid tumors. Cancer Treat Rev, 26, 269-86. https://doi.org/10.1053/ctrv.2000.0176
  13. Hirasawa Y, Kohno N, Yokoyama A, et al (2000). Natural autoantibody to MUC1 is a prognostic indicator for nonsmall cell lung cancer. Am J Respir Crit Care Med, 161, 589-94. https://doi.org/10.1164/ajrccm.161.2.9905028
  14. Hobday TJ (2005). An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer, 5, S11-8. https://doi.org/10.3816/CCC.2005.s.002
  15. Howat JM, Moore M, Hilton AM, Kimber I (1979). Inhibition of antibody-dependent cellular cytotoxicity by artificial immune complexes and pathological sera. Immunology, 37, 467-75.
  16. Hull SR, Bright A, Carraway KL, et al (1989). Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun, 1, 261-7.
  17. Ishizaki H, Manuel ER, Song GY, et al (2011). Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother, 60, 99-109. https://doi.org/10.1007/s00262-010-0923-0
  18. Kameshima H, Tsuruma T, Torigoe T, et al (2011). Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci, 102, 1181-7. https://doi.org/10.1111/j.1349-7006.2011.01918.x
  19. Karanikas V, Khalil S, Kerenidi T, Gourgoulianis KI, Germenis AE (2009). Anti-survivin antibody responses in lung cancer. Cancer Lett, 282, 159-66. https://doi.org/10.1016/j.canlet.2009.03.015
  20. Lladser A, Parraga M, Quevedo L, et al (2006). Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Immunobiology, 211, 11-27. https://doi.org/10.1016/j.imbio.2005.08.002
  21. Megliorino R, Shi FD, Peng XX, et al (2005). Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev, 29, 241-8. https://doi.org/10.1016/j.cdp.2005.03.002
  22. Meyerhard. JA., Mayer RJ (2005). Systemic therapy for colorectal cancer. N Engl J Med, 352, 476-87. https://doi.org/10.1056/NEJMra040958
  23. Midgley RS, Yanagisawa Y, Kerr DJ (2009). Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol, 6, 108-20. https://doi.org/10.1038/ncpgasthep1337
  24. Nakamura H, Hinoda Y, Nakagawa N, et al. (1998). Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol, 33, 354-61. https://doi.org/10.1007/s005350050096
  25. Penland S K, Goldberg RM (2004). Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park), 18, 715-22, 727; discussion 727-9.
  26. Rohayem J, Diestelkoetter P, Weigle B, et al (2000). Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res, 60, 1815-7.
  27. Silk AW, Schoen RE, Potter DM, Finn OJ (2009). Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol, 47, 52-6. https://doi.org/10.1016/j.molimm.2008.12.025
  28. Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH (2011). Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines, 10, 899-921. https://doi.org/10.1586/erv.11.63
  29. Tang CK, Katsara M, Apostolopoulos V (2008). Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines, 7, 963-75. https://doi.org/10.1586/14760584.7.7.963
  30. Tang Y, Wang L, Zhang P, et al (2010). Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol, 17, 1903-8. https://doi.org/10.1128/CVI.00142-10
  31. Toubi E, Shoenfeld Y (2007). Protective autoimmunity in cancer (review). Oncol Rep, 17, 245-51.
  32. Wan DS (2009). Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng, 28, 897-902.
  33. Yagihashi A, Ohmura T, Asanuma K, et al (2005). Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta, 362, 125-30. https://doi.org/10.1016/j.cccn.2005.06.009
  34. Yip KW, Shi W, Pintilie M, et al (2006). Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res, 12, 5726-32. https://doi.org/10.1158/1078-0432.CCR-06-0571
  35. Yuan S, Shi C, Ling R, et al (2010). Immunization with two recombinant Bacillus Calmette-Guerin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol, 136, 1359-67. https://doi.org/10.1007/s00432-010-0787-x
  36. Zhang HH, Zhang SZ, Zhao DH, et al (2008). Construction and expression of human survivin and preparation of its polyclonal antibody. Chem Res Chinese Universities, 24, 767-70.
  37. Zhang JY, Casiano CA, Peng XX, et al (2003). Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev, 12, 136-43.

Cited by

  1. Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress? vol.10, pp.4, 2014, https://doi.org/10.1007/s11888-014-0250-5
  2. Immunosignature: Serum Antibody Profiling for Cancer Diagnostics vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4833
  3. The potential role of immunotherapy to treat colorectal cancer vol.24, pp.3, 2015, https://doi.org/10.1517/13543784.2015.985376
  4. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.335
  5. Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5075